HPV Assay Adjunctive Use With Pap Test Needs U.S. Patient Data - FDA Panel
This article was originally published in The Gray Sheet
Executive Summary
Foreign clinical data supporting human papilloma virus (HPV) testing as an adjunct to Pap smear in screening for cervical cancer need to be confirmed in U.S. studies, FDA's Microbiology Devices Panel recommended at its recent meeting in Gaithersburg, Maryland.
You may also be interested in...
NCI HPV Trial Data Re-Evaluated By Digene To Support PMA Supplement
Digene will reanalyze clinical data and specimens from a 23,702-patient trial in Portland, Oregon, prior to seeking a primary screening indication for its HybridCapture 2 HPV test. The Gaithersburg, Maryland firm expects to file a PMA supplement by year-end.
NCI HPV Trial Data Re-Evaluated By Digene To Support PMA Supplement
Digene will reanalyze clinical data and specimens from a 23,702-patient trial in Portland, Oregon, prior to seeking a primary screening indication for its HybridCapture 2 HPV test. The Gaithersburg, Maryland firm expects to file a PMA supplement by year-end.
HPV Assays With Pap Smears Could Safely Lengthen Screening Intervals
Use of human papillomavirus (HPV) DNA screening assays with conventional Pap smears could safely allow for women to wait longer intervals between cervical screenings, Jack Cuzick, PhD, noted in a Jan. 5 teleconference coinciding with the same-day publication of his editorial in the Journal of the American Medical Association.